Abstract. Lymph node metastasis (LNM) in oral squamous cell carcinoma (OSCC) is known to associate with a significant decrease of 5-year survival. Genetic factors related to the difference of the LNM status in the OSCC have been not fully elucidated. Array-based comparative genomic hybridization (CGH) with individual gene-level resolution and real-time quantitative polymerase chain reaction (QPCR) were conducted using primary tumor materials resected from 54 OSCC patients with (n=22) or without (n=32) cervical LNM. Frequent gain was observed at the 11q13 region exclusively in patients with cervical LNM, which was confirmed by real-time QPCR experiments using 11 genes (TPCN2, MYEOV, CCND1, OR AOV1, FGF4, TMEM16A, FA DD, PPFIA1, CT TN, SHANK2 and DHCR7) in this region. It was revealed that two distinct amplification cores existed, which were separated by a breakpoint between MYEOV and CCND1 in the 11q13 region. The combination of copy number amplification at CTTN (core 2) and/or TPCN2/MYEOV (core 1), selected from each core, was most significantly associated with cervical LNM (P=0.0035). Two amplification cores at the 11q13 region may have biological impacts on OSCC cells to spread from the primary site to local lymph nodes. Further study of a larger patient series should be conducted to validate these results.
Introduction
Oral squamous cell carcinoma (OSCC) is a common malignancy that affects 300,000 individuals per year worldwide (1) . Despite diagnostic and therapeutic improvements in surgical techniques, radiotherapy, and chemotherapy, the prognosis of OSCC has remained dismal, as approximately 50% of patients die within 5 years (1, 2) . Studies have shown that cervical lymph node metastasis (LNM) is strongly correlated with poor prognosis, such as increased risk of distant metastasis, recurrence at the primary site, and reduction in the 5-year survival rate (3) (4) (5) . Sentinel lymph node biopsy is a technique that facilitates detection of the LNM and reduction of morbidity in patients. Common diagnostic technologies such as computed tomography (CT) and magnetic resonance imaging (MRI) have shown unsatisfactory sensitivity and specificity for the detection of LNM. Though, the sensitivity of 18F-FDG PET is significantly higher than that of CT/MRI. Their specificities appeared to be similar. Visual correlation of PET and CT/MRI showed a trend of increased diagnostic accuracy; however, its sensitivity is still not high enough to replace pathologic lymph node staging based on surgical dissection (6) .
The mechanisms by which OSCC cells spread from the primary site to cervical lymph nodes is not fully understood. A mouse model of the cervical LNM was established by Sun et al (7) . Among three human OSCC cell lines implanted into the nude mouse, one cell line exhibited significantly high rate of LNM, indicating important roles of inherent differences of OSCC cells in the potential of LNM. Cytogenetic analyses in conjunction with molecular genetics analyses by many research groups have revealed accumulation of genetic abnormalities during development and/or progression of OSCC (8) . Recent advances in tumor molecular biology have revealed chromosomal rearrangements at the level of individual genes in the whole human genome.
Because chromosomal abnormalities can influence individual cancer characteristics, comparative genomic hybridization (CGH) has been used extensively to find LNM-associated chromosomal abnormalities in OSCC patients (9) . Such CGH studies have identified several chromosomal regions, including 11q13, but the regions have yet to be proven as reliable prognostic markers. Array-based CGH using BAC clones (10, 11) has improved the resolution of analysis to the level of several hundred kilo base regions. Currently, arraybased CGH using in situ synthesized oligonucleotides (12) available to provide superior resolution at the level of individual genes in the whole human genome. Xu et al (13) reported on the correlation between DNA copy number abnormality and expression in 11q13.2-11q13.3 using both the array-based CGH and the gene expression microarray techniques, and identified genes associated with poor survival in metastatic OSCC patients. In this study, an oligonucleotide array-based CGH was applied to screen LNM-associated abnormalities of genes in a subpopulation of Japanese OSCC patients. The purpose of this study was to identify a reliable prognostic marker related to LNM in this population. Using a larger patient series, further mapping of corresponding gene regions was conducted by real-time quantitative PCR (QPCR) to elucidate the correlation among those regions.
Patients and methods
Patient characteristics. Fifty-four Japanese patients with OSCC were included in the present study. Surgical resection of primary tumors and marginal normal tissues from all patients was performed at the Hospital of Tokyo Dental College, Chiba, Japan, between July 1999 and September 2006. The ethics committees of the Tokyo Dental College and the National Institute of Radiological Sciences approved the present study. Informed consent was obtained from each patient before surgical resection.
Staging of tumors was performed according to the International Union Against Cancer TNM staging system (14) . Cervical LNM during the 24-month follow-up period was evaluated by both CT and MRI. In case of a positive signal, metastasis was further confirmed by histopathological examination of resected tissues. Patients absent of any cervical LNM for 24 months after surgery were considered metastasisfree. Patients with distant metastasis at the time of clinical examination or those receiving preventive radiotherapy or chemotherapy were excluded from this study. Detailed patient characteristics are shown in Table I .
Primary tumor samples.
Resected primary tumor tissues were divided into two pieces. One piece was frozen immediately in liquid nitrogen and stored at -80˚C. The other one was fixed in 10% formalin for histopathological examination. The resected marginal normal tissues were frozen immediately in liquid nitrogen and stored at -80˚C.
DNA extraction and quantification. DNA from the frozen tumor and marginal normal tissues was extracted using the QIAamp tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The amount of extracted DNA was quantified by PicoGreen dsDNA quantitation reagent (Invitrogen, Carlsbad, CA).
Array-based CGH. Array-based CGH for primary tumor samples was performed using a Human Genome CGH Microarray Kit 44K (Agilent Technologies, Santa Clara, CA), which contains in situ synthesized 60-mer oligonucleotides representing 42,494 unique probes for human genes. Labeling and hybridization were performed essentially as described elsewhere (19) , with the following modifications. We amplified 100 ng each of reference (male or female human genomic DNA; Promega, Madison, wI) and tumor DNA with Phi29 DNA polymerase according to the supplier's protocols (Qiagen); DNA was then digested with AluI (50 U) and RsaI (50 U; Promega) for 2 h at 37˚C. Digests were filtered using the QIAprep Spin Miniprep kit (Qiagen) and then verified with Bioanalyzer (Agilent Technologies). Fluorescent labeling reactions to make hybridization probes were performed with 7 µg of purified restricted DNA using a BioPrime array CGH genomic labeling kit (Invitrogen), according to the manufacturer's instructions, in a volume of 50 µl with a modified dUTP pool containing 120 µM each of dATP, dGTP, Table I . Clinical characteristics of the 54 OSCC patients. Before hybridization to the array, the hybridization mixtures were denatured at 95˚C for 3 min then incubated at 37˚C for 30 min. The mixtures were centrifuged at 17,900 x g for 1 min to remove any precipitate and then applied to the array using an Agilent microarray hybridization chamber. Hybridization was carried out for 40 h at 65˚C in a rotating oven (Robbins Scientific, Mountain View, CA) at 20 rpm. The arrays were then disassembled in 0.5X SSC/0.005% Triton X-102 at room temperature then washed for 5 min at room temperature in wash 1, followed by 1 min at 37˚C in 0.1X SSC/0.005% Triton X-102 (wash 2). Slides were dried and scanned using an Agilent G2565B DNA microarray scanner.
Image data analysis. Array-based CGH images were analyzed using Feature Extraction software (Ver. 8.5.1.1, Agilent Technologies). The linear normalization method was applied to the all datasets, and signals from negative control features were used for background subtraction. Datasets resulting from dye-swap experiments were averaged and then further analyzed using CGH Analytics software (Ver. 3.4, Agilent Technologies).
Real-time QPCR. Real-time QPCR was performed using tumor or marginal normal tissue samples with SYBR Green I fluorescence detection on a LightCycler 480 (Roche Diagnostics, Basel, Switzerland). Oligonucleotide primers for real-time QPCR were designed using Primer 3 software (whitehead Institute for Biomedical Research), and uniqueness in the human genome was checked by a BLAST search. Nucleotide sequences of oligonucleotide primers are listed in Table II . The 20-µl reaction mixture consisted of 10 µl 2X iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA), 2.5 ng genomic DNA, and 800 nM of each PCR primer. The reaction mixtures were heated at 95˚C for 10 min and then subjected to 40 rounds of two-step temperature cycling [95˚C for 15 sec and 65˚C for 60 sec; (15)]. The crossing point for each amplification curve was determined by the second derivative maximum method. The standard curve method using separate reaction wells was applied for relative quantification. The copy numbers are presented as the log 2 ratio of each target locus in tumor normalization to an internal reference loci (N-acetylglucosamine kinase, NAGK; 16) and relative to the reference DNA, calculated as follows: copy number = (target loci dosage of tumor DNA/target loci dosage of reference DNA)/(reference loci dosage of tumor DNA/reference loci dosage of reference DNA). A log 2 ratio >0.59 was set as the cutoff value for copy number amplification. Statistical analysis. The association between copy number amplification and LNM was assessed by Fisher's exact test.
The LNM-free survival curve was plotted by the Kaplan-Meier method using StatView version 5.0 (SAS Institute, Cary, NC).
Pearson's correlation coefficients were used to determine the degree of correlation between the incidence data of two genes. The log+rank test was used to compare differences in LNM-free survival between the two groups. A P<0.05 was considered to indicate statistical significance.
Results
This study included 54 patients who had undergone surgical resection of primary OSCC. Twenty-two patients had histopathologically confirmed cervical LNM at the time of diagnosis or during the 24-month follow-up period (LNM present). Patients with distant metastasis at the time of diagnosis were not included in this study. Mean age, gender, tumor site, and T classification were not significantly different between the two groups (Table I) .
Array-based CGH analysis. Ten patients from each group (LNM present or LNM absent) were subjected to array-based CGH analysis to screen for LNM-associated gene abnormalities in this population. A total of 231 of 42,494 probes were eliminated from the dataset because they exceeded the limit of deviation between the dye-swap duplicated data in at least one patient. The array-based CGH karyogram is shown in Fig. 1 . Previous CGH studies have shown that gains in 3q, 5p, 8q, 9q, 11q, and 20q and losses in 3p, 4q, 8p, 9p, and 18q are common chromosomal alterations in OSCC patients (17) (18) (19) (20) . A total of 48 gain regions including six previously reported segments (3q, 5p, 8q, 9q, 11q, and 20q) and 31 loss regions including four previously reported segments (3p, 8p, 9p, and 18q) were found in the LNM-present group. In contrast, 32 gain regions including three previously reported segments (3q, 5p, and 8q) and 26 loss regions including three previously reported segments (3p, 8p, and 21q) were found in the LNM-absent group. Among these, gain at the 11q13 region was the only chromosomal abnormality that reached a frequency of 30% exclusively in one group (LNM present; Fig. 2 ).
Assessment of genes in the 11q13 region by QPCR.
To evaluate array-based CGH data at the 11q13 region, real-time QPCR was performed using non-amplified genomic DNA as a template. Initially, seven PCR primer sets located respectively in TPCN2, MYEOV, ORAOV1, PPFIA1, CTTN, SHANK2, and DHCR7 of the 11q13 region were successfully designed to meet the criteria for reliable quantification at exactly the same position as corresponding probes on the CGH array (Table II and Fig. 3A) . One PCR primer set was designed in a housekeeping gene, NAGK located on chromosome 2, as a reference for normalization. Real-time QPCR analysis was performed with the above primer sets using genomic DNA of the 20 previously analyzed patients and of sex-matched references, resulting in generation of 140 overlapping data. The correlation coefficient between the array-based CGH data and real-time QPCR data was 0.68, indicating moderate reproducibility between the two methods. Additional PCR primer sets were designed in adequate place of genes such as CCND1, FGF4, TMEM16A, and FADD, that initial primer design at the probe site failed to meet the criteria (Table II and Fig. 3A ). These 11 primer sets were then used for real-time QPCR analysis of all 54 patients. As shown in Fig. 3B and C, the individual amplification regions spanning from CCND1 to CTTN showed regional variations in the degree of amplification and indicated genetic Table III ). QPCR analysis of DNA from marginal normal tissues was performed in 30 patients whose DNA samples were available. The log 2 ratio was measured for CCND1, PPFIA1, CTTN, and SHANK2, and no copy number amplification of these genes was observed in marginal normal tissues. The log 2 ratio data using reference genomic DNA (Promega) and the log 2 ratio data using DNA from marginal normal tissue indicated generally high consistency (R 2 = 0.89; data not shown).
Evaluation of amplification core structure in the 11q13 region.
The OSCC patients exhibit various patterns of copy number amplifications and the minimal overlapping region of amplification was ~0.77 Mb, including nine known genes (CCND1, ORAOV1, FGF19, FGF4, FGF3, TMEM16A, FADD, PPFIA1, and CTTN). To elucidate the relationships among genes within this amplification region, analyses of correlation between sets of gene pairs were performed. According to the resulting R 2 values, there were two hypothetical cores in the 11q13 region: core 1 spanned from TPCN2 to MYEOV and core 2 spanned from CCND1 to CTTN (Fig.4) . The highest R 2 value was between CTTN and PPFIA1 (R 2 = 0.98). Presence of two cores in the 11q13 amplification region indicates that a breakpoint might be located at the 5' terminus of CCND1 gene.
Prognostic value of 11q13 copy number amplification for cervical LNM. To examine the prognostic value of 11q13 copy number amplification for cervical LNM, we first evaluated the association of amplification of individual genes with cervical LNM. Because no LNM-absent patient showed amplification of DHCR7, we excluded this gene from the analysis. CCND1, FGF4, and CTTN showed statistically significant associations with cervical LNM (P<0.05; Table IV) . we next investigated the association between prognosis and combinations of various amplified genes. Combination of copy number amplification Table III . Number of patients who had amplified genes.
Number of amplified genes in the 11q13 region at CTTN (core 2) and/or TPCN2/MYEOV (core 1), which were selected from each core separated by the novel breakpoint, showed the strongest association with cervical LNM (P=0.0035). when cervical LNM-free survival was plotted by the KaplanMeier method, the data showed that LNM was significantly higher in those patients with CTTN and/or TPCN2/MYEOV amplification (P=0.001; Fig. 5 ).
Discussion
The 11q13 region contains numerous functional genes relevant to metastasis or poor prognosis (21) (22) (23) . Thus, understanding the variable contributions of these genes, as shown by the non-uniform nature of their amplification, may be a key for more precise prediction of metastasis and survival. Our findings revealed two cores in the 11q13 region, core 1 (TPCN2, MYEOV) and core 2 (CCND1, ORAOV1, FGF4, TMEM16A, FADD, PPFIA1, and CTTN), with a breakpoint at 11.32 kb centromeric to CCND1. Our analyses also indicated that two-gene combinations can be used as LNM predictive markers ( Fig. 5 and Table IV) . Studies have shown that LNM is strongly correlated with poor prognosis (3) (4) (5) . Based on chromosomal CGH and bacterial artificial chromosome CGH arrays, studies have reported several genes as prognostic markers for LNM (9, 24) . we used high-resolution array-based CGH as an initial screening method, and to our knowledge, this is the first report of an oligonucleotide array-based CGH for primary Japanese OSCC. Our findings concur with those of other reports, namely that a gain in the 11q13 region was the only chromosomal abnormality that reached a frequency of 30% exclusively in the LNM-present group (Fig. 2) .
Breaking of the DNA double strand is the initial step of gene amplification, and proto-oncogenes are clustered around recombination hotspots or fragile sites. The homogeneously staining region (HSR) involving 11q13 includes amplified genes from this chromosome segment (25) and carries a relatively poor prognosis in OSCC patients (26, 27) . Several reports have suggested that HSR formation result from breaks in fragile sites, based on findings that gaps or breaks form at these sites in metaphase chromosomes when cells are grown under conditions that interfere with DNA replication or repair (28) (29) (30) . The breakage of DNA at these fragile sites led Coquelle et al (28) to propose the breakage-fusion-bridge cycle model. Recently, Reshmi et al (31) provided experimental evidence that 11q13 gene amplification in OSCC cells occurs via breakage-fusionbridge cycles. It is of great interest to elucidate detail of breakage structure between the two core segments in future study.
In this study, TPCN2 and MYEOV were indentified biomarker of LNM, and theses two genes showed high correlation (Fig. 4) . Xu et al (13) provided that correlation between DNA copy number abnormality and expression in 11q13.2-11q13.3. TPCN2 showed high correlation between DNA copy number abnormality and expression, while M YEOV showed no significant correlation. Thus TPCN2 might be functionally important, whereas the copy number abnormality of MYEOV might act as just surrogate marker.
Our findings indicate that CTTN amplification has a high prognostic value in OSCC patients. CTTN is an actin-associated scaffolding protein, which binds and activates the actin-related protein 2/3 complex, and thus regulates the branched actin networks in the formation of dynamic cortical actin-associated structures (32, 33) . Functional analysis in breast cancer and head and neck squamous cell carcinoma patients has revealed that CTTN promotes invasiveness of cancer cells (21, 34) . Huang et al (35) reported no association between LNM and amplification status or expression of 10 genes in the 11q13 region in OSCC patients, although another OSCC study indicated that both ORAOV1 and CTTN amplifications were significantly associated with the presence of LNM (36) . ORAOV1 regulates cell cycle and apoptosis in cervical cancer HeLa cells. Furthermore amplification and overexpression of CTTN was correlated with LNM in esophageal squamous cell carcinoma patients (23) . Table IV lists other candidate genes that may be associated with LNM. FGF4 was reported to have an association with LNM in OSCC patients (24) . Although cDNA microarray analysis revealed overexpression of FADD in OSCC patients, no correlation was found with cervical LNM (37) . In lung adenocarcinoma patients increased FADD mRNA and protein were significantly associated with poor outcome (38) .
we used 20 patients with T 1 or T 2 group for array-based CGH. we unexpectedly found that two patients in the LNM-absent group also showed 11q13 amplification ( Fig. 3 and Table III ). Because there is a possibility of cervical LNM in the future, it is important to follow-up carefully.
We refined the comprehensive physical map of the 11q13 amplification region and found two core regions separated by a novel breakpoint. Copy number amplification of CTTN (core 2) and/or TPCN2/MYEOV (core 1) in the 11q13 region was strongly associated with LNM in OSCC patients. Detailed assessment of selected loci followed by real-time QPCR appears to be a good strategy for identifying genetic markers in regions with complicated alterations, as is the case with 11q13. Further study of a larger patient series should be conducted to validate these results.
